Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression analyses of COCs treated with N-Cadherin antagonist CRS-006

ABSTRACT: Gene expression analyses of COCs treated with N-Cadherin antagonist CRS-006

PROVIDER: PRJNA707001 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13863700.fastq.gz	Fastqsanger.gz
	SRR13863701.fastq.gz	Fastqsanger.gz
	SRR13863702.fastq.gz	Fastqsanger.gz
	SRR13863703.fastq.gz	Fastqsanger.gz
	SRR13863704.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 7

Similar Datasets

Gene expression analyses of whole ovaries from mice that were treated with N-Cadherin antagonist CRS-006

Project description:Gene expression analyses of whole ovaries from mice that were treated with N-Cadherin antagonist CRS-006

| PRJNA707003 | ENA

Gene expression analyses of COCs treated with N-Cadherin antagonist CRS-006

Project description:N-Cadherin is a cell surface protein that is critical for cell-cell adhesion and is essential for structural integrity of tissues. In the ovary, it is expressed by granulosa cells and cumulus cells junctions throughout ovarian development. Importantly, it is also present between oocyte (egg) and surround cumulus cells, and is the only physical type of communication that is present between the egg and its surrounding cells.

2024-03-04 | GSE168347 | GEO

Gene expression analyses of whole ovaries from mice that were treated with N-Cadherin antagonist CRS-006

2024-03-04 | GSE168348 | GEO

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Project description:This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.

| 2267503 | ecrin-mdr-crc

Liver transcriptome analysis after DF-006 treatment in an HBV mouse model

Project description:A new chemical entity, DF-006, has been shown to suppress HBV replication in an AAV-HBV mouse model. DF-006 activates NF-kB signaling. In order to elucidate the mechanism of action of DF-006, specifically the genes expression stimulated in the liver that mediated its anti-HBV efficacy, we perform deep sequencing of RNA samples taken from AAV-HBV mice 4 hours after 10 μg/kg DF-006 oral administration or vehicle control. AAV-HBV mouse models were established by injecting male C57B6/J mice with 1011 vg/mouse AAV-HBV (genotype D, serotype ayw, GenBank accession number: KX449554). Dosing with DF-006 resulted in a statistically significant increase of gene expression for 1,685 genes in the liver. We performed an over-representation analysis for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and found 53 pathways were significantly enriched. The top 10 pathways included those that involved viral infection (e.g., herpes, influenza, Epstein-Barr, hepatitis B, measles) and those that involved host innate responses (TNF, osteoclast differentiation, NF-κB, toll-like receptor, RIG-I -like receptor). qPCR analysis confirmed genes that are directly or indirectly induced through NF-kB pathway and are reported before to play a role in HBV suppression.

2022-08-11 | GSE210856 | GEO

Analysis of gene expression changes in MLL-rearranged leukaemia cell lines with induced resistance against CCI-006

Project description:Gene expression analysis of two MLL-r leukaemia cell lines (SM6p2 and SM6p3) and the parental PER-485 MLL-rearranged leukaemia cell line they were derived from by continuous culturing in CCI-006. SM6p2 and SM6p3 thereby developed induced resistance against the compound. The aim of this experiment was to identify any gene expression changes in SM6p2 and SM6p3 cells induced by continuous culturing in CCI-006, thereby potentially providing insight into the mechanisms of primary and induced resistance of MLL-rearranged leukaemia cell lines against the cytotoxic compound CCI-006.

2019-06-01 | GSE115794 | GEO

AhR antagonist

Project description:AhR antagonist

| PRJNA766233 | ENA

Gene expression analysis of a MLL-rearranged leukaemia cell line, PER-485, treated with small molecule CCI-006.

Project description:A phenotypic cell-based high-throughput screen identified a novel small molecule, CCI-006 with selective cytotoxic activity against MLL-rearranged leukaemia cell lines. The aim of this experiment was to identify the mechanism of action of CCI-006 by investigating the gene expression changes induced in a MLL-rearranged leukaemia cell line following a short incubation with the compound.

2019-06-01 | GSE115793 | GEO

Clostridium saccharobutylicum strain:006

Project description:Clostridium saccharobutylicum 006 genome sequencing

| PRJNA347169 | ENA

Pseudoalteromonas spongiae UST010723-006

Project description:Pseudoalteromonas spongiae UST010723-006 Genome sequencing

| PRJNA77687 | ENA